Mr. Kazandjian accumulates over 24 years of experience in venture capital, both as a start-up entrepreneur, and as a venture-capitalist. As President of CDC-Innovation, an important French venture-capital fund, from 1998 to 2002, he raised over 250 M€ of capital, and had 300 M€ of funds under management. The performance of the funds are situated in the top ten percent of European venture-capital funds. All along his career as a managing partner of venture funds, Mr. Kazandjian has supervised over 70 investments in technology start-ups. He was directly associated with the inception of several European companies (ExonHit Therapeutics, Entomed, Neurotech, Arpida, Immutep) as well as North-American technology companies (Qbiogene, Cryocath Technologies, Drug Abuse Sciences, Eyeweb), and has held numerous board positions. Raffy Kazandjian holds an engineering degree from the Chemistry Engineering School of Paris, and is a graduate from MIT(MS’85) and from the European Business School INSEAD (MBA’90). Specialties: UBT has a track record of adding significant value to formative-stage companies, providing management, financial, business development and strategic basis for a company’s growth and success. Two Areas of expertise. 1) Assistance to Life Science Companies, incl. critical business plan reviews, coaching, assistance in M&A, fund raising. 2) Venture advisor to biotech funds, encompassing portfolio management, management of exits, board representation.